Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Abstract

<p class="first" id="d6831518e209"> <b>Publisher's Note:</b> There is an <span class="generated">[Related article:]</span>Inside <i>Blood</i> Commentary on this article in this issue. </p><p id="d6831518e224"> <div class="list"> <a class="named-anchor" id="d6831518e226"> <!-- named anchor --> </a> <ul class="so-custom-list"> <li id="d6831518e227"> <div class="so-custom-list-content so-ol"> <p class="first" id="d6831518e228">Survival of patients with MF after ruxolitinib discontinuation is poor, with median survival of 14 months. </p> </div> </li> <li id="d6831518e230"> <div class="so-custom-list-content so-ol"> <p class="first" id="d6831518e231">Low platelets at the start or end of therapy or clonal evolution while on therapy are associated with an even worse prognosis. </p> </div> </li> </ul> </div> </p><p class="first" id="d6831518e235">Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients’ survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets &lt;260 × 10 ⁹/L at the start of therapy or &lt;100 × 10 ⁹/L at the time of discontinuation were associated with shorter survival after discontinuation. Of 62 patients with molecular data at baseline and follow-up, 22 (35%) acquired a new mutation while receiving ruxolitinib (14 [61%] in <i>ASXL1</i>). Patients showing clonal evolution had significantly shorter survival after discontinuation (6 vs 16 months). Transfusion dependency was the only clinical variable associated with clonal evolution. These findings underscore the need for novel therapies and suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be markers of poor prognosis. </p>